Effects of octreotide on fecal characteristics and humoral immunity in neonates with necrotizing enterocolitis

doi:10.11958/20240801

Abstract

Abstract:

Objective To observe the effects of octreotide on fecal characteristics and humoral immunity in neonates with necrotizing enterocolitis (NEC). Methods A retrospective study was conducted on 60 newly born NEC patients at Hebei PetroChina Central Hospital from March 2022 to September 2023. The patients were separated into the observation group (30 cases) and the routine group (30 cases) based on treatment methods. The conventional group was treated with total parenteral nutrition and gastrointestinal decompression plus piperacillin sodium and tazobactam sodium for 7 days. The observation group was treated with octreotide in addition to the routine group for 5 days. The treatment efficacy, general clinical data, degree of intestinal microbiota disorder, expression levels of intestinal microbiota markers and immune indicators were compared between the two groups. Results The total effective rate of the observation group was higher than that of the routine group (P<0.05). After treatment, body weight of the observation group was higher than that of the routine group. The hospitalization time, vomiting relief time, abdominal distension relief time, diarrhea relief time and complete recovery time of fecal characteristics were lower in the observation group than those in the routine group. Compared with before treatment, the degree of intestinal microbiota disorder and high mobility group box protein 1 (HMGB1) were reduced in both groups after treatment, and expression levels of human β defensin 2 (HBD2), autoinducer-2 (AI-2) and serum immunoglobulin (Ig) A, IgG and IgM were increased (P<0.05). After treatment, HMGB1 was lower in the observation group than that in the routine group, while HBD2, AI-2 and serum IgA, IgG and IgM were higher than those in the routine group (P<0.05). Conclusion Octreotide can effectively treat children with NEC, improve stool characteristics, and enhance immunity.

Key words: enterocolitis, necrotizing, infant, newborn, octreotide, immunity, humoral, fecal characteristics

CLC Number:

R725.7

Figures/Tables 6

References 20

[1]	杨义, 杨敏, 何清, 等. 新生儿坏死性小肠结肠炎并发穿孔的危险因素分析[J]. 辽宁医学杂志, 2023, 37(5):4-9.
	YANG Y, YANG M, HE Q, et al. Risk factors of perforation in neonatal necrotizing enterocolitis[J]. Liaoning Medical Journal, 2023, 37(5):4-9.
[2]	李燕, 于瑞娜, 王娇娇, 等. 肠道超声在新生儿坏死性小肠结肠炎急性期手术中的预测价值[J]. 中华小儿外科杂志, 2021, 42(6):526-530.
	LI Y, YU R N, WANG J J, et al. Prognostic value of intestinal ultrasound in acute stage of neonatal necrotizing enterocolitis[J]. Chinese Journal of Pediatric Surgery, 2021, 42(6):526-530. doi:10.3760/cma.j.cn421158-20200509-00318.
[3]	SHIN S H, KIM E K, LEE K Y, et al. TNF-α antagonist attenuates systemic lipopolysaccharide-induced brain white matter injury in neonatal rats[J]. BMC Neurosci, 2019, 20(1):45. doi:10.1186/s12868-019-0529-1.
[4]	MARTYNOV I, RAEDECKE J, KLIMA-FRYSCH J, et al. The outcome of Bishop-Koop procedure compared to divided stoma in neonates with meconium ileus,congenital intestinal atresia and necrotizing enterocolitis[J]. Medicine(Baltimore), 2019, 98(27):e16304. doi:10.1097/MD.0000000000016304.
[5]	王春晖, 杨洁, 杜春艳, 等. 奥曲肽联合深度水解配方奶粉在新生儿坏死性小肠结肠炎中的应用效果及对血清PA、MTL水平的影响[J]. 临床医学研究与实践, 2021, 6(35):31-33.
	WANG C H, YANG J, DU C Y, et al. Effect of octreotide combined with deeply hydrolyzed formula on neonatal necrotizing enterocolitis and its effect on serum PA and MTL levels[J]. Clinical Medicine Research and Practice, 2021, 6(35):31-33. doi:10.19347/j.cnki.2096-1413.202135009.
[6]	唐军, 封志纯, 母得志, 等. 新生儿坏死性小肠结肠炎临床诊疗指南(2020)[J]. 中国当代儿科杂志, 2021, 23(1):1-11.
	TANG J, FENG Z C, MU D Z, et al. Clinical guidelines for the diagnosis and treatment of neonatal necrotizing enterocolitis(2020)[J]. Chinese Journal of Contemporary Pediatrics, 2021, 23(1):1-11. doi:10.7499/j.issn.1008-8830.2011145.
[7]	BELL M J, TERNBERG J L, FEIGIN R D, et al. Neonatal necrotizing enterocolitis. Therapeutic decisions based upon clinical staging[J]. Ann Surg, 1978, 187(1):1-7. doi:10.1097/00000658-197801000-00001.
[8]	陈永红. 儿科疾病诊断与疗效标准[M]. 上海: 上海中医药大学出版社, 2006:12-14.
	CHEN Y H. Diagnostic and therapeutic criteria for pediatric diseases[M]. Shanghai: Shanghai University of Traditional Chinese Medicine Press, 2006:12-14.
[9]	张秀荣, 周峻元. 肠道菌粪便涂片检查图谱[M]. 北京: 人民军医出版社, 2000:63-65.
	ZHANG X R, ZHOU J Y. Atlas of fecal smear examination of intestinal bacteria[M]. Beijing: People's Military Medical Press, 2000:63-65.
[10]	JIANG S Y, YAN W L, LI S J, et al. Mortality and morbidity in infants <34 weeks′ gestation in 25 NICUs in China:a prospective cohort study[J]. Front Pediatr, 2020, 8:33. doi:10.3389/fped.2020.00033.
[11]	JONES I H, HALL N J. Contemporary outcomes for infants with necrotizing enterocolitis-a systematic review[J]. J Pediatr, 2020, 220:86-92.e3. doi:10.1016/j.jpeds.2019.11.011.
[12]	BAZACLIU C, NEU J. Necrotizing enterocolitis:long term complications[J]. Curr Pediatr Rev, 2019, 15(2):115-124. doi:10.2174/1573396315666190312093119.
[13]	HICKEY M, GEORGIEFF M, RAMEL S. Neurodevelopmental outcomes following necrotizing enterocolitis[J]. Semin Fetal Neonatal Med, 2018, 23(6):426-432. doi:10.1016/j.siny.2018.08.005.
[14]	张丽. 奥美拉唑联合奥曲肽治疗消化性溃疡合并上消化道出血的临床效果观察[J]. 基层医学论坛, 2023, 27(1):8-10.
	ZHANG L. Clinical effect of omeprazole combined with octreotide in the treatment of peptic ulcer complicated with upper gastrointestinal bleeding[J]. Primary Medicine Forum, 2023, 27(1):8-10. doi:10.19435/j.1672-1721.2023.01.003.
[15]	秦毅, 李翠竹, 隆妮. 双歧杆菌三联活菌胶囊联合奥曲肽治疗新生儿坏死性小肠结肠炎的疗效分析[J]. 中国处方药, 2021, 19(9):115-116.
	QIN Y, LI C Z, LONG N. Therapeutic effect of Bifidobacterium triple live capsule combined with octreotide on neonatal necrotizing enterocolitis[J]. China Prescription Drugs, 2021, 19(9):115-116. doi:10.3969/j.issn.1671-945X.2021.09.053.
[16]	陈伟霞, 陈维捷, 吕爱君. 奥曲肽治疗新生儿坏死性小肠结肠炎的临床效果研究[J]. 中国实用医药, 2020, 15(5):130-132.
	CHEN W X, CHEN W J, LV A J. Clinical effect of octreotide on neonatal necrotizing enterocolitis[J]. Chinese Journal of Practical Medicine, 2020, 15(5):130-132. doi:10.14163/j.cnki.11-5547/r.2020.05.058.
[17]	冉亚林, 蒋秋容. 粪便HMGB1、AI-2和HBD2在新生儿坏死性小肠结肠炎中的临床意义及与肠道菌群的关系[J]. 国际检验医学杂志, 2022, 43(1):78-82,89.
	RAN Y L, JIANG Q R. Clinical significance of fecal HMGB1,AI-2 and HBD2 in neonatal necrotizing enterocolitis and their relationship with intestinal flora[J]. International Journal of Laboratory Medicine, 2022, 43(1):78-82,89. doi:10.3969/j.issn.1673-4130.2022.01.016.
[18]	毕小朵, 杨轶男. 白色念球菌对小鼠阴道内β-防御素-2表达的影响[J]. 中国生物制品学杂志, 2018, 31(12):1336-1339.
	BI X D, YANG Y N. Effects of Candicoccus albicans on the expression of β-defensin-2 in the vagina of mice[J]. Chinese Journal of Biologics, 2018, 31(12):1336-1339. doi:10.13200/j.cnki.cjb.002387.
[19]	付春燕, 李禄全, 肖洒, 等. 粪便AI-2测定对应用广谱抗生素后新生儿肠道菌群变化的预测价值[J]. 解放军医学杂志, 2020, 45(6):618-622.
	FU C Y, LI L Q, XIAO S, et al. The value of faecal AI-2 determination in predicting the change of intestinal flora in neonates after application of broad spectrum antibiotics[J]. Journal of Chinese People's Liberation Army Medicine, 2020, 45(6):618-622. doi:10.11855/j.issn.0577-7402.2020.06.07.
[20]	XIONG T, MAHESHWARI A, NEU J, et al. An overview of systematic reviews of randomized-controlled trials for preventing necrotizing enterocolitis in preterm infants[J]. Neonatology, 2020, 117(1):46-56. doi:10.1159/000504371.

指标	性别		胎龄/周	出生体质量/g
指标	男	女	胎龄/周	出生体质量/g
常规组	14（46.67）	16（53.33）	34.07±4.31	2 346.27±482.54
观察组	12（40.00）	18（60.00）	33.13±4.25	2 469.83±513.41
χ²或t	0.271		0.884	0.961

指标	性别		胎龄/周	出生体质量/g
指标	男	女	胎龄/周	出生体质量/g
常规组	14（46.67）	16（53.33）	34.07±4.31	2 346.27±482.54
观察组	12（40.00）	18（60.00）	33.13±4.25	2 469.83±513.41
χ²或t	0.271		0.884	0.961

组别	显效	有效	无效	总有效
常规组	1（3.33）	18（60.00）	11（36.67）	19（63.33）
观察组	3（10.00）	24（80.00）	3（10.00）	27（90.00）
χ²				5.963^＊

组别	显效	有效	无效	总有效
常规组	1（3.33）	18（60.00）	11（36.67）	19（63.33）
观察组	3（10.00）	24（80.00）	3（10.00）	27（90.00）
χ²				5.963^＊

组别	体质量/g			住院时间/d		呕吐缓解时间/d
常规组	2 603.83±523.48			44.80±5.82		2.23±0.43
观察组	2 885.50±548.62			40.23±5.68		1.47±0.51
t	2.034^＊			3.076^＊＊		6.312^＊＊
组别		腹胀缓解时间/d	腹泻缓解时间/d		粪便性状恢复时间/d
常规组		3.83±0.38	3.67±0.48		5.27±0.69
观察组		2.37±0.49	2.20±0.41		4.63±0.61
t		12.965^＊＊	12.775^＊＊		3.749^＊＊